riluzole has been researched along with Osteosarcoma in 4 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
Excerpt | Relevance | Reference |
---|---|---|
"Our lab has previously demonstrated Riluzole to be an effective drug in inhibiting proliferation and inducing apoptosis in both human and mouse osteosarcoma." | 8.02 | Riluzole-induced apoptosis in osteosarcoma is mediated through Yes-associated protein upon phosphorylation by c-Abl Kinase. ( Azeem, SM; Blyufer, A; Cecilio, L; ChandThakuri, S; Chowdhury, Y; Hasnat, R; Huang, YQ; Lhamo, S; Mahajan, SS; Raghubir, M; Rahman, CN; Tam, C; Tariq, I; Wong, L; Yan, S; Zhagui, R, 2021) |
"In human osteosarcoma MG63 cells, the effect of the neuroprotective drug riluzole on the intracellular Ca(2+) concentration ([Ca(2+)](i)) was measured using fura-2." | 7.71 | Effect of riluzole on cytosolic Ca2+ increase in human osteosarcoma cells. ( Chang, HT; Huang, JK; Jan, CR; Jiann, BP; Lu, YC, 2002) |
"Osteosarcomas are the most commonly occurring malignant bone cancer in young individuals." | 5.56 | Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice. ( Fang, J; Mahajan, SS; Matsui, H; Raghubir, M; Rahman, CN, 2020) |
"Thus Riluzole is an effective drug to inhibit proliferation and survival of osteosarcoma cells and has therapeutic potential for the treatment of osteosarcoma exhibiting autocrine glutamate signaling." | 5.46 | Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole. ( Ait Taouit, L; Basu-Roy, U; Gulzar, H; Houssou, M; Jaikaran, T; Kozlitina, K; Liao, S; Mahajan, SS; Mansukhani, A; Ruiz, Y; Schvarts, Y; Yelskaya, Z, 2017) |
"Our lab has previously demonstrated Riluzole to be an effective drug in inhibiting proliferation and inducing apoptosis in both human and mouse osteosarcoma." | 4.02 | Riluzole-induced apoptosis in osteosarcoma is mediated through Yes-associated protein upon phosphorylation by c-Abl Kinase. ( Azeem, SM; Blyufer, A; Cecilio, L; ChandThakuri, S; Chowdhury, Y; Hasnat, R; Huang, YQ; Lhamo, S; Mahajan, SS; Raghubir, M; Rahman, CN; Tam, C; Tariq, I; Wong, L; Yan, S; Zhagui, R, 2021) |
"In human osteosarcoma MG63 cells, the effect of the neuroprotective drug riluzole on the intracellular Ca(2+) concentration ([Ca(2+)](i)) was measured using fura-2." | 3.71 | Effect of riluzole on cytosolic Ca2+ increase in human osteosarcoma cells. ( Chang, HT; Huang, JK; Jan, CR; Jiann, BP; Lu, YC, 2002) |
"Osteosarcomas are the most commonly occurring malignant bone cancer in young individuals." | 1.56 | Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice. ( Fang, J; Mahajan, SS; Matsui, H; Raghubir, M; Rahman, CN, 2020) |
"Thus Riluzole is an effective drug to inhibit proliferation and survival of osteosarcoma cells and has therapeutic potential for the treatment of osteosarcoma exhibiting autocrine glutamate signaling." | 1.46 | Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole. ( Ait Taouit, L; Basu-Roy, U; Gulzar, H; Houssou, M; Jaikaran, T; Kozlitina, K; Liao, S; Mahajan, SS; Mansukhani, A; Ruiz, Y; Schvarts, Y; Yelskaya, Z, 2017) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
Raghubir, M | 2 |
Azeem, SM | 1 |
Hasnat, R | 1 |
Rahman, CN | 2 |
Wong, L | 1 |
Yan, S | 1 |
Huang, YQ | 1 |
Zhagui, R | 1 |
Blyufer, A | 1 |
Tariq, I | 1 |
Tam, C | 1 |
Lhamo, S | 1 |
Cecilio, L | 1 |
Chowdhury, Y | 1 |
ChandThakuri, S | 1 |
Mahajan, SS | 3 |
Fang, J | 1 |
Matsui, H | 1 |
Liao, S | 1 |
Ruiz, Y | 1 |
Gulzar, H | 1 |
Yelskaya, Z | 1 |
Ait Taouit, L | 1 |
Houssou, M | 1 |
Jaikaran, T | 1 |
Schvarts, Y | 1 |
Kozlitina, K | 1 |
Basu-Roy, U | 1 |
Mansukhani, A | 1 |
Jan, CR | 1 |
Lu, YC | 1 |
Jiann, BP | 1 |
Chang, HT | 1 |
Huang, JK | 1 |
4 other studies available for riluzole and Osteosarcoma
Article | Year |
---|---|
Riluzole-induced apoptosis in osteosarcoma is mediated through Yes-associated protein upon phosphorylation by c-Abl Kinase.
Topics: Apoptosis; bcl-2-Associated X Protein; Bone Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Survival | 2021 |
Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice.
Topics: Animals; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Compo | 2020 |
Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cel | 2017 |
Effect of riluzole on cytosolic Ca2+ increase in human osteosarcoma cells.
Topics: Calcium; Cytosol; Dose-Response Relationship, Drug; Humans; Osteosarcoma; Riluzole; Tumor Cells, Cul | 2002 |